Wellington Management Group LLP 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-10 10:25 am Purchase |
2024-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Wellington Management Group LLP | 5,307,326 8.200% |
688,967 (+14.92%) |
Filing |
| 2024-11-08 10:52 am Sale |
2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR |
Wellington Management Group LLP | 4,618,359 7.170% |
-197,199 (-4.10%) |
Filing |
| 2024-02-08 10:21 am Purchase |
2023-12-29 | 13G | Kymera Therapeutics, Inc. KYMR |
Wellington Management Group LLP | 4,815,558 8.680% |
224,469 (+4.89%) |
Filing |
| 2023-02-06 3:02 pm Purchase |
2022-12-30 | 13G | Kymera Therapeutics, Inc. KYMR |
Wellington Management Group LLP | 4,591,089 8.370% |
1,896,275 (+70.37%) |
Filing |
| 2022-02-04 09:27 am Purchase |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Wellington Management Group LLP | 2,694,814 5.240% |
2,694,814 (New Position) |
Filing |